Amy Ko

Platelet gene expression and function in patients with COVID-19

Targeted glycan degradation potentiates the anticancer immune response in vivo

Programmed cell removal by calreticulin in tissue homeostasis and cancer

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis

The JAK/STAT signaling pathway: from bench to clinic

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

Ambulatory Varicosity avUlsion Later or Synchronized (AVULS)

Compression regimes after endovenous ablation for superficial venous insufficiency – A survey of members of the Vascular Society of Great Britain and Ireland

JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Mechanochemical ablation for the treatment of superficial venous incompetence: A cohort study of a single centre’s early experience

Superficial venous insufficiency from the infernal to the endothermal

Compliance with NICE guidelines when commissioning varicose vein procedures

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Platelets Endocytose Viral Particles and Are Activated via TLR (Toll-Like Receptor) Signaling

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN

Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms

Incidence of Varicose Veins, Chronic Venous Insufficiency, and Progression of the Disease in the Bonn Vein Study II

Dynamin 2–dependent endocytosis is required for normal megakaryocyte development in mice